Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03562832 | Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the 2X-121 DRP | PHASE2 | COMPLETED | 20 | — | — | Jun 20, 2018 | Aug 1, 2024 | Jan 23, 2025 | 2 | Denmark |
Overall tumor response according to RECIST
| Arm | Type | Description |
|---|---|---|
| PARP inhibitor 2X-121 | EXPERIMENTAL | 600 mg PARP inhibitor 2X-121 as single daily oral agent in mBC patients |
| Name | Type | Description |
|---|---|---|
| PARP inhibitor 2X-121 | DRUG | 600 mg PARP inhibitor 2X-121 as single daily oral agent in mBC patients |
Inclusion Criteria: * Signed informed consent form. * Age 18 years or older. * Histologically or cytological documented mBC (independent of hormone receptor, HER2 status and BRCA1 or 2 status) relapsed in 2 or more different prior therapies. * Measurable disease by CT scan or MRI. * With a drug res...